Status:
COMPLETED
A Clinical Study on Ozone Autohemotherapy for the Treatment of Acute Ischemic Stroke
Lead Sponsor:
The First Affiliated Hospital of Zhengzhou University
Conditions:
Acute Ischemic Cerebrovascular Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Clinical studies applying ozonated autohemotherapy to treat acute cerebrovascular diseases have validated the safety and efficacy of this treatment, as well as explored its mechanism of action.
Eligibility Criteria
Inclusion
- Confirmed by cranial CT or MRI examination, first-ever stroke, hospital admission within \<24 hours of symptom onset,
- age \>18 years,
- NIHSS score between 4 and 15,
- TOAST classification as large artery atherosclerosis,
- complete clinical records, minimum follow-up period of ≥3 months post-discharge,
- willingness to undergo brachial blood puncture treatment, and provision of informed consent
Exclusion
- other neurological disorders, cerebral infarction caused by vertebral-basilar artery disease, cardioembolic stroke, or large-vessel vasculitis, acute or chronic infectious diseases, autoimmune or hematologic disorders, malignant tumors, mental abnormalities, severe heart, liver, or kidney dysfunction, intracerebral hemorrhage, and craniocerebral surgery history.
- Contraindications for ozone therapy included hyperthyroidism, favism, severe coagulation disorders, and abnormal puncture site barriers
Key Trial Info
Start Date :
August 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 31 2022
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT06525792
Start Date
August 1 2020
End Date
October 31 2022
Last Update
July 29 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fifth Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China, 450000